NCT03894254

Brief Summary

The Alzheimer's disease or related disorders (ADRD) are among the most disabling diseases because of their main features such as cognitive impairment, loss of functional autonomy and behavioural disorders. In absence of current curative treatment, the identification of the predictive risk factors of progression of the disease, evaluated through its main symptoms, represents a major stake of public health. The Investigators aim at developing a regional database, which includes the patient medical records on a prospective basis, in collaboration with the medical and administrative staff and with the University hospital computer science departments. The main objective is to study the predictive factors associated with change in functional autonomy level, measured every 6 to 12 months in centres across Region Auvergne Rhone-Alpes in France. The real-life study population will consist in about 5400 patients with ADRD. The inclusion period will be of 3 years, the length of follow-up of each patient will be of 10 years max for a total study length of 13 years.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,400

participants targeted

Target at P75+ for not_applicable

Timeline
71mo left

Started Sep 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

5 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress50%
Sep 2020Mar 2032

First Submitted

Initial submission to the registry

March 25, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 28, 2019

Completed
1.5 years until next milestone

Study Start

First participant enrolled

September 9, 2020

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2024

Completed
8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2032

Expected
Last Updated

May 2, 2022

Status Verified

April 1, 2022

Enrollment Period

3.5 years

First QC Date

March 25, 2019

Last Update Submit

April 25, 2022

Conditions

Outcome Measures

Primary Outcomes (3)

  • Functional autonomy level

    The Lawton Instrumental Activities of Daily Living (IADL)

    from 6 months to 12 months interval

  • Functional autonomy level

    The Disability Assessment of Dementia (DAD-6)

    from 6 months to 12 months interval

  • Functional autonomy level

    The New-AGGIR (French national score for dependency assessment)

    from 6 months to 12 months interval

Study Arms (1)

Patients with subjective cognitive complaint or neurocognitive

EXPERIMENTAL

: Real-life cohort patients with subjective cognitive complaint or neurocognitive disorders undergoing medical examination in memory centers, and for whom extensive evaluations will be performed for the study

Other: no intervention

Interventions

This is study carried out in current practice. Patients are undergoing a medical examination in a memory center, with extensive and systematic evaluations for the study involving the following tests: IADL, DAD6, New AGGIR, NPI, and mini-Zarit) assessing the functions (autonomy, behavior and caregiver burden).

Patients with subjective cognitive complaint or neurocognitive

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged 18 years and older, undergoing a medical visit in a memory center or neuro-cognition service
  • Patients living at home or in housing
  • Patients with memory impairment, at all stage of the disease

You may not qualify if:

  • Patients in institution
  • Patients under legal protection
  • Patients with a hearing or visual impairment, which prevents carrying out examinations

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Hôpital Dugoujon

Caluire-et-Cuire, 69300, France

RECRUITING

Centre Hospitalier Lyon Sud

Lyon, 69310, France

RECRUITING

Service de neuro-cognition et neuro-ophtalmologie du Groupement Hospitalier Est

Lyon, France

RECRUITING

CHU Saint-Etienne

Saint-Etienne, 42055, France

RECRUITING

Centre Mémoire de Ressources et de Recherche de Lyon

Villeurbanne, 69100, France

RECRUITING

MeSH Terms

Conditions

Memory Disorders

Condition Hierarchy (Ancestors)

Neurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Pierre Krolak-Salmon, PhD

    Centre Mémoire de Ressources et de Recherche

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Pierre Krolak-Salmon, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 25, 2019

First Posted

March 28, 2019

Study Start

September 9, 2020

Primary Completion

March 1, 2024

Study Completion (Estimated)

March 1, 2032

Last Updated

May 2, 2022

Record last verified: 2022-04

Data Sharing

IPD Sharing
Will not share

Locations